Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Severe colitis in patients with melanoma treated with BRAF/MEK inhibitors.

Alimentary pharmacology & therapeutics - 1 Apr 2023

Carbonnel Franck, Routier Emilie, Lazure Thierry, Mussini Charlotte, Bellanger Christophe, Merklen Carine, Bejou Bakhtiar, Buisson Anthony, Amiot Aurélien, Meyer Antoine, Dong Catherine, Robert Caroline

Abstract excerpt

BACKGROUND AND AIMS: Dual blockade of BRAF and MEK kinases is a standard of care for metastatic V600E/K BRAF mutant melanoma. This study reports the first systematic description of colitis due to BRAF and MEK inhibitors. METHODS: We studied consecutive patients with melanoma, treated with BRAF and MEK inhibitors, who had colitis requiring hospitalisation. Electronic files were studied; endoscopic biopsies and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Proto-Oncogene Proteins B-raf
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Mitogen-Activated Protein Kinase Kinases

Share to Mutation

Share to Neoplasm Recurrence, Local

Share to Protein Kinase Inhibitors

Share to Skin Neoplasms

Source

Identifiers

PMID: 36578099
DOI: 10.1111/apt.17352

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Severe colitis in patients with melanoma treated with BRAF/MEK inhibitors.PMID 36578099Read ↗

Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study.Semantic proximity Read ↗

Drug-induced colitis on BRAF and MEK inhibitors for BRAF V600E-mutated non-small cell lung cancer: a case report.Semantic proximity Read ↗

A More Severe Non-melanoma Skin Cancer Phenotype Is Seen in Patients with Inflammatory Bowel Disease on Tumor Necrosis Factor-α Antagonists.Semantic proximity Read ↗

Nivolumab treatment in a patient with BRAF mutant advanced melanoma and liver failure with encephalopathy.Semantic proximity Read ↗

Truth or dare: switching BRAF/MEK inhibitors after acute interstitial nephritis in a patient with metastatic melanoma - A case report and review of the literature.Semantic proximity Read ↗

Effectiveness, safety and utilization of cobimetinib and vemurafenib in patients with BRAF V600 mutant melanoma with and without cerebral metastasis under real-world conditions in Germany: the non-interventional study coveNIS.Semantic proximity Read ↗

Association of Antibiotic Exposure With Survival and Toxicity in Patients With Melanoma Receiving Immunotherapy.Semantic proximity Read ↗

Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.